1. | | Recruiting | Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma; Anxiety Disorder; childhood acute myeloid leukemia and other myeloid malignancies; ... |
2. | | Recruiting | CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
3. | | Recruiting | Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
4. | | Recruiting | Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
5. | | Recruiting | Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
6. | | Recruiting | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
7. | | Recruiting | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis |
8. | | Recruiting | Antineoplaston Therapy in Treating Patients With Multiple Myeloma Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
9. | | Recruiting | High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis |
10. | | Recruiting | Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
11. | | Not yet recruiting | Melphalan and Amifostine Followed By Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
12. | | Not yet recruiting | Dexamethasone With or Without CC-5013 in Treating Patients With Newly Diagnosed Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
13. | | Recruiting | Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
14. | | Recruiting | Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
15. | | Recruiting | Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
16. | | Recruiting | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection |
17. | | Recruiting | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
18. | | Recruiting | Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II or Stage III Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
19. | | Recruiting | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
20. | | Recruiting | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma Condition: Multiple Myeloma |
21. | | Recruiting | Study Comparing Skeletal Targeted Radiotherapy (STR) plus Melphalan to Melphalan Alone, with Stem Cell Transplant in Multiple Myeloma Condition: Multiple Myeloma |
22. | | Recruiting | Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma Condition: Multiple Myeloma |
23. | | Recruiting | A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 Condition: Multiple Myeloma |
24. | | Recruiting | Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma Condition: Multiple Myeloma |
25. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma |
26. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma |
27. | | Recruiting | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma |
28. | | Recruiting | High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis Conditions: primary systemic amyloidosis; stage II multiple myeloma; stage III multiple myeloma |
29. | | Recruiting | Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma |
30. | | Recruiting | Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma |
31. | | Recruiting | Safety and Efficacy of Atiprimod for Patients with Refractory Multiple Myeloma Condition: Multiple Myeloma |
32. | | Recruiting | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally Condition: Multiple Myeloma |
33. | | Recruiting | Study of Combination PS-341 and Thalidomide in Multiple Myeloma Condition: Multiple Myeloma |
34. | | Recruiting | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma Condition: Multiple Myeloma |
35. | | Recruiting | Xcellerated T CellsTM in Patients with Multiple Myeloma Condition: Multiple Myeloma |
36. | | Recruiting | Combined Bone Marrow and Kidney Transplant for Multiple Myeloma with Kidney Failure Conditions: Kidney Failure, Chronic; Multiple Myeloma |
37. | | Recruiting | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Conditions: Hematologic Disease; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorder |
38. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
39. | | Recruiting | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Condition: Multiple Myeloma |
40. | | Not yet recruiting | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma Condition: Multiple Myeloma |
41. | | Recruiting | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant Condition: Multiple Myeloma |
42. | | Recruiting | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) Condition: Multiple Myeloma |
43. | | Recruiting | UARK 2003-33, Total Therapy III Condition: Multiple Myeloma |
44. | | Recruiting | Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma Condition: Multiple Myeloma |
45. | | Recruiting | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients with Multiple Myeloma Condition: Multiple Myeloma |
46. | | Recruiting | Double Cord Blood Transplant Study Conditions: Leukemia, Lymphocytic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Chronic; Lymphoma, Non-Hodgkin; Multiple Myeloma |
47. | | Recruiting | Safety Study of AP23573 in Patients with Advanced, Refractory or Recurrent Malignancies Conditions: Tumors; Lymphoma; Multiple Myeloma |
48. | | Recruiting | Safety and pharmacokinetics of orally administered gallium maltolate in various refractory malignancies. Conditions: Prostatic Neoplasms; Multiple Myeloma; Bladder Neoplasms; Lymphoma |
49. | | Recruiting | Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H Conditions: Myelodysplastic Disorders; Leukemia; Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoproliferative Disorders |
50. | | Recruiting | Blood and Marrow Transplant Clinical Research Network Conditions: Bone Marrow Transplantation; Blood Disease; Hematopoietic Stem Cell Transplantation; Leukemia; Multiple Myeloma; Myelodysplastic Syndromes; ... |